# Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype

> **NCT00808184** · PHASE4 · COMPLETED · sponsor: **National University Hospital, Singapore** · enrollment: 25 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** CPT-11, Raltegravir (Isentress®), Midazolam

## Key facts

- **NCT ID:** NCT00808184
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2012-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00808184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00808184, "Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00808184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*